Building on its expanding IP foundation, Lurex Bio’s portfolio—including the NeoTag™, Atraxis™, and Atraxis-X™ platforms—aims to overcome one of oncology’s [...]
Lurex Bio, Inc., a biotechnology company pioneering next-generation immunotherapy platforms, today announced the filing of multiple U.S. provisional patents to [...]